Addition of sotatercept to existing therapy shows promise for the treatment of pulmonary arterial hypertension

News Medical

Center

Mixed Factuality

Other: Ian Birkby

Addition of sotatercept to existing therapy shows promise for the treatment of pulmonary arterial hypertension

Patients with pulmonary arterial hypertension (PAH), a severe, progressive condition that affects the heart and lungs, who were treated with the novel first-in-class medication sotatercept on top of existing therapy experienced significant improvements in walking distance via a six-minute walking test—the study's primary endpoint and a validated surrogate for functional improvement and reduced symptom burden.